26 articles
2,2'-dithiodiethanesulfonic acid
2,2'-Dithiodiethanesulfonic acid (dimesna free acid, bis(2-sulfoethyl) disulfide, CAS 45127-11-5) is the disulfide dimer of mesna; its disodium salt is the investigational chemoprotectant BNP7787/Tavocept/LP-300, reduced to mesna in the kidney to detoxify cisplatin and ifosfamide metabolites.
Bleomycin/vinblastine
Bleomycin/vinblastine is a combination chemotherapy pairing of a DNA-cleaving antibiotic with a vinca alkaloid, used in regimens for germ cell tumors and Hodgkin lymphoma, including ABVD.
Bleomycin/vincristine chemotherapy regimen
The bleomycin/vincristine pairing is a two-drug combination used inside named chemotherapy regimens such as Stanford V, BEACOPP, and BACOP, principally for Hodgkin lymphoma, non-Hodgkin lymphoma, and germ cell tumors.
BrECADD regimen
BrECADD is a combination chemotherapy regimen for advanced-stage classical Hodgkin lymphoma, combining brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; it outperformed eBEACOPP in the HD21 phase 3 trial.
CHOP (chemotherapy)
CHOP is a combination chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone, used mainly to treat non-Hodgkin lymphoma; with rituximab added, R-CHOP cures about 70% of diffuse large B-cell lymphoma cases.
CHOP regimen
The CHOP regimen combines cyclophosphamide, doxorubicin, vincristine, and prednisone to treat non-Hodgkin lymphoma, with R-CHOP, its rituximab-added form, the standard frontline treatment for diffuse large B-cell lymphoma.
Dose-adjusted EPOCH regimen
Dose-adjusted EPOCH (DA-EPOCH) is a combination chemotherapy regimen for aggressive B-cell lymphomas, including Burkitt lymphoma, with doses adjusted each cycle to the patient's neutrophil nadir.
EP regimen
The EP regimen, also written as PE, is a chemotherapy doublet of etoposide and cisplatin used mainly for small cell lung cancer and germ cell tumors including testicular cancer.
EPOCH chemotherapy regimen
EPOCH is a combination chemotherapy regimen of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, with the natural-product drugs given by continuous infusion; it is used mainly for aggressive B-cell non-Hodgkin lymphoma, and adding rituximab gives R-EPOCH.
FLAG-IDA regimen
FLAG-IDA, also known as FLAG-Ida, is an intensive chemotherapy regimen combining fludarabine, high-dose cytarabine, idarubicin, and G-CSF, used mainly for relapsed or refractory acute myeloid leukemia in patients under 60.
FLOT chemotherapy
FLOT chemotherapy combines docetaxel, oxaliplatin, leucovorin, and fluorouracil in two-week cycles around surgery for stomach and esophageal adenocarcinoma, replacing ECF as the standard after the FLOT4-AIO trial.
FLOT regimen
The FLOT regimen is a combination chemotherapy of docetaxel, fluorouracil, leucovorin, and oxaliplatin given every 14 days, used mainly as perioperative treatment for resectable gastric and gastroesophageal junction adenocarcinoma.
FOLFIRI
FOLFIRI is a cyclic intravenous chemotherapy regimen combining irinotecan, fluorouracil, and leucovorin, repeated every 14 days, used mainly as first-line treatment for metastatic colorectal cancer.
FOLFIRINOX
FOLFIRINOX is a four-drug chemotherapy regimen combining folinic acid, fluorouracil, irinotecan, and oxaliplatin, used first-line for metastatic pancreatic cancer, where it outperformed gemcitabine, and in modified form after resection.
FOLFOX chemotherapy
FOLFOX, also known as Oxaliplatin de Gramont or OxMdG, is a combination chemotherapy regimen of folinic acid, fluorouracil, and oxaliplatin, used mainly to treat colorectal cancer.
FOLFOXIRI
FOLFOXIRI is a combination chemotherapy regimen pairing infusional fluorouracil with leucovorin, oxaliplatin, and irinotecan in two-weekly cycles, used mainly as first-line treatment for metastatic colorectal cancer.
ICE chemotherapy regimen
The ICE chemotherapy regimen combines ifosfamide, carboplatin, and etoposide, used mainly as salvage treatment for relapsed or refractory Hodgkin and non-Hodgkin lymphoma, often before stem cell transplantation.
IE regimen (chemotherapy)
The IE regimen, also known as the Ifosfamide-Etoposide Rhabdomyosarcoma Regimen, pairs ifosfamide with etoposide for five days, used front-line and as salvage therapy for rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma.
Ifosfamide/doxorubicin regimen
The ifosfamide/doxorubicin (ID, or Dox-Ifos) regimen is a combination chemotherapy pairing ifosfamide with doxorubicin, given in 21-day cycles mainly to treat soft-tissue sarcomas, including rhabdomyosarcoma.
Pola-R-CHP regimen
Pola-R-CHP is a combination chemotherapy regimen for previously untreated diffuse large B-cell lymphoma in which the vincristine of R-CHOP is replaced by polatuzumab vedotin, approved in the US in 2023.
Prednisone/vincristine regimen
The prednisone/vincristine regimen is a historical two-drug combination chemotherapy induction treatment for acute lymphoblastic leukemia, credited with complete remission rates of 83 to 95% and still embedded in named oncology regimens.
R-CHOP regimen
R-CHOP is a combination immunochemotherapy regimen pairing the antibody rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; standard first-line treatment for diffuse large B-cell lymphoma since 2006, curing roughly 60 to 70% of patients.
R-DHAP regimen
R-DHAP is a combination chemotherapy regimen of rituximab with dexamethasone, high-dose cytarabine, and cisplatin, used mainly as salvage therapy for relapsed CD20-positive B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma, usually before stem cell transplant.
R-EPOCH regimen
R-EPOCH is a six-drug chemoimmunotherapy regimen for B-cell non-Hodgkin lymphoma combining rituximab with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, given partly by 96-hour continuous infusion.
Vincristine and dactinomycin regimen
The vincristine and dactinomycin (VA) regimen, also called Actinomycin-D/Vincristine, is a two-drug intravenous chemotherapy combination used to treat low-risk childhood rhabdomyosarcoma and forming the core of the VAC backbone.
XELOX regimen
XELOX, also called CAPOX or OX, is a chemotherapy regimen combining oral capecitabine with intravenous oxaliplatin, used mainly for colorectal and other gastrointestinal cancers, and is an alternative to FOLFOX.